文献速递造血干细胞移植与细胞治疗

奥拉帕利联合镭-223对比镭-223治疗转移性去势抵抗性前列腺癌骨转移的多中心随机II期试验(COMRADE)

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).
PubMed 文献 · J Clin Oncol · 2026-05-07

COMRADE研究纳入120例mCRPC伴≥2处骨转移患者,随机接受奥拉帕利联合镭-223或镭-223治疗。

要点

  • 奥拉帕利联合镭-223显著改善mCRPC骨转移患者的rPFS(中位8.9 vs 4.7个月,HR 0.50)。
  • 既往未接受多西他赛及骨转移灶≤20处的患者获益更明显。
  • 联合组≥3级血液学毒性增加,但整体可控。

核心结论

  • 奥拉帕利联合镭-223较镭-223单药显著延长mCRPC骨转移患者的影像学无进展生存期。
  • 联合方案虽增加血液学毒性,但总体可管理,支持进一步探索DNA损伤靶向策略。

研究设计与样本

  • 多中心、随机、II期试验,纳入120例mCRPC伴≥2处骨转移的男性患者。
  • 1:1随机分配至奥拉帕利(200 mg每日两次)联合镭-223(55 kBq/kg静脉,每4周一次×6次)或镭-223单药,允许进展后交叉。
  • 主要终点为研究者评估的影像学无进展生存期(rPFS)。

主要发现

  • 既往未接受多西他赛患者中位rPFS为13.7 vs 5.7个月(HR 0.24,90% CI 0.15–0.40)。
  • 骨转移灶≤20处患者中位rPFS为13.4 vs 4.2个月(HR 0.21,90% CI 0.13–0.33)。
  • 1年症状性骨骼相关事件累积发生率联合组为12.7%,镭-223组为22.9%。
  • 中位总生存期两组相似(20.2 vs 21.1个月)。

关键数值与推荐

  • ≥3级治疗相关不良事件发生率联合组56%,镭-223组33%。
  • 常见≥3级血液学毒性:淋巴细胞减少31% vs 9.1%,贫血22% vs 16%,血小板减少6.8% vs 3.6%。

临床怎么用

  • 对于mCRPC伴骨转移患者,奥拉帕利联合镭-223可显著延长rPFS,尤其适合未接受多西他赛或骨转移负荷较低者。
  • 联合方案需密切监测血液学毒性,尤其是淋巴细胞减少、贫血和血小板减少。

局限性

  • II期试验样本量有限,总生存期未见差异,需进一步验证。
  • 交叉设计可能影响生存分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radium-223 is an α-emitting radiopharmaceutical that improves survival in metastatic castration-resistant prostate cancer (mCRPC). Preclinical data suggest synergy between poly(ADP-ribose) polymerase (PARP) inhibition and radiation. After phase I dose-finding, we conducted a randomized phase II trial to assess efficacy and safety of this combination versus radium-223. PATIENTS AND METHODS: Men with mCRPC and ≥2 bone metastases (BM) were randomly assigned 1:1 to olaparib (200 mg twice daily) plus radium-223 (55 kBq/kg intravenous once every 4 weeks × 6 doses) or radium-223. Crossover was allowed at progression. The primary end point was investigator-assessed radiographic progression-free survival (rPFS). RESULTS: A total of 120 patients were randomly assigned. Most had prior androgen receptor pathway inhibitor exposure (96%), 52% had received docetaxel, 47% had >20 BM, and 90% received bone-protecting agents. The combination significantly improved rPFS (median 8.9 v 4.7 months; hazard ratio [HR], 0.50 [one-sided 90% CI, 0.35 to 0.70]; one-sided P = .0042). The benefit was most pronounced in patients without prior docetaxel (13.7 v 5.7 months; HR, 0.24 [90% CI, 0.15 to 0.40]) and those with ≤20 BM (13.4 v 4.2 months; HR, 0.21 [90% CI, 0.13 to 0.33]). The 1-year cumulative incidence of symptomatic skeletal-related events was lower with the combination (12.7% v 22.9%). Median overall survival was similar (20.2 v 21.1 months). Grade ≥3 treatment-related adverse events occurred in 56% versus 33% (combination v radium-223), primarily hematologic, including lymphopenia (31% v 9.1%), anemia (22% v 16%), and thrombocytopenia (6.8% v 3.6%). CONCLUSION: Olaparib plus radium-223 significantly prolonged rPFS compared with radium-223 in men with mCRPC and BM. Despite increased hematologic toxicity, the regimen was manageable and supports further exploration of DNA damage-targeted strategies in this population.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. McKay RR, Xie W, Ajmera A, et al. Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE). J Clin Oncol. 2026. PMID: 42096662. doi:10.1200/JCO-25-02835

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。